{"id":"NCT02284035","sponsor":"Juan A. Arnaiz","briefTitle":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","officialTitle":"Pilot 24week Clinical Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Raltegravir/Lamivudine Combination, Replacing Standard Combination Therapy in HIV-infected Pts With Prolonged Virological Suppression.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-27","primaryCompletion":"2017-02-28","completion":"2017-02-28","firstPosted":"2014-11-05","resultsPosted":"2025-07-20","lastUpdate":"2025-07-20"},"enrollment":75,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["AIDS"],"interventions":[{"type":"DRUG","name":"Raltegravir/3TC","otherNames":[]},{"type":"DRUG","name":"EFV/TDF/FTC","otherNames":["NNRTI-Based Regimen"]},{"type":"DRUG","name":"ATV/r + TDF/FTC or DRV/r + TDF/FTC","otherNames":["PI-Based Regimens"]},{"type":"DRUG","name":"DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC","otherNames":["INSTI-Based Regimens"]},{"type":"DRUG","name":"EFV plus ABC/3TC or RPV/TDF/FTC","otherNames":["NNRTI-Based Regimens"]},{"type":"DRUG","name":"ATV/r plus ABC/3TC","otherNames":["PI-Based Regimen"]},{"type":"DRUG","name":"DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC","otherNames":["PI-Based Regimens"]},{"type":"DRUG","name":"RAL plus ABC/3TC","otherNames":["INSTI-Based Regimen"]},{"type":"DRUG","name":"Other ART regimens","otherNames":[]}],"arms":[{"label":"Group 1 Raltegravir / 3TC (MK0518B","type":"EXPERIMENTAL"},{"label":"Group 2 standard combination therapy","type":"ACTIVE_COMPARATOR"}],"summary":"A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard combination therapy in HIV-infected patients with prolonged virological suppression","primaryOutcome":{"measure":"Proportion of Patients Free of Therapeutic Failure","timeFrame":"24 weeks","effectByArm":[{"arm":"Group 1 Raltegravir / 3TC (MK0518B","deltaMin":47,"sd":null},{"arm":"Group 2 Standard Combination Therapy","deltaMin":20,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":49},"commonTop":["Amigdalitis","Insomnia","Lues","Dizziness","Ansiety"]}}